Platform Card - Brellium

Clinical quality, supervision, and compliance platform for ABA providers.

Most recent review: October 2026

Brellium is an AI-enabled clinical quality assurance and supervision platform designed to help ABA organizations monitor documentation quality, treatment integrity, and supervisory oversight at scale. Rather than functioning as a practice management system, Brellium operates as a complementary layer alongside existing PM and billing platforms.

Originally focused on behavioral health and hospice, Brellium is expanding into broader healthcare markets, including primary care and medical specialties. ABA remains a core market as the company extends its technology across additional care settings.

What the Platform Does

Brellium automates quality assurance across clinical documentation, treatment plans, and supervision workflows. Its configurable review capabilities help organizations identify documentation and compliance issues, including those affecting authorization readiness, before they become downstream operational problems.

The platform's CortexLM architecture analyzes patient visit documentation against organization-specific requirements to identify gaps in care quality and compliance, supporting structured feedback and corrective action.

Brellium also provides visibility into quality trends across clinicians and locations, shifting quality assurance from retrospective auditing toward more proactive clinical oversight.

The platform is particularly relevant for providers operating at scale, including those managing distributed clinical teams, navigating payor scrutiny, or seeking greater consistency in documentation and supervisory practices.

Where It Fits in the ABA Stack

Primary domain
Clinical Documentation & Measurement

Related domains
People, Hiring & Credentialing
Data, Analytics & Orchestration

Brellium is not a system of record. It operates as a specialized clinical quality assurance layer alongside existing practice management and billing platforms.

Its integrations with Motivity and RethinkFirst illustrate how specialized QA capabilities are becoming more closely connected to core ABA operating workflows without replacing the underlying systems.

Platform Direction

Brellium announced an additional $23 million investment in October 2026, led by Left Lane Capital with participation from First Round Capital. The investment supports continued product development and expansion beyond behavioral health and hospice into additional healthcare specialties.

The introduction of CortexLM reflects an effort to apply a common quality and compliance architecture across different clinical settings while accommodating organization-specific requirements.

For ABA providers, the strategic question is how Brellium balances investment in specialized ABA workflows with the development of capabilities intended for a broader healthcare market.

Coverage on MissionViewpoint

Brellium appears in MissionViewpoint analysis related to clinical quality assurance, supervision models, compliance infrastructure, and the growing importance of defensible clinical processes in scaled ABA organizations.

→ View all MissionViewpoint coverage related to Brellium

Coverage may expand over time as additional analysis is published.